A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil^® in Healthy Volunteers Aged 15–35 Years

<b>Background/Objectives:</b> Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies. Although licensed HPV vaccines are highly effective, access remains limited in many low- and middle-income countries du...

Descripció completa

Dades bibliogràfiques

Autors principals:	Erfan Pakatchian, Minoo Mohraz, Mohammad Taghavian, Babak Javadimehr, Hajar Mohammadi Barzelighi, Majid Teymoori-Rad, Mehrdad Ghodsi, Zahra Naderi Saffar
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2026-06-01
Col·lecció:	Vaccines
Matèries:	human papillomavirus HPV vaccine quadrivalent HPV vaccine Gardisun Gardasil immunogenicity
Accés en línia:	https://www.mdpi.com/2076-393X/14/6/540
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!